Edoxaban versus placebo, aspirin, or aspirin plus clopidogrel for stroke prevention in atrial fibrillation: An indirect comparison analysis

Thrombosis and Haemostasis

Volumn 114, Issue 2, 2015, Pages 403-409

  Blann, Andrew D ^a   Skjoth, Flemming ^b,c   Rasmussen, Lars H ^b,c   Larsen, Torben B ^b,c   Lip, Gregory Y H ^a,b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b AALBORG UNIVERSITY   (Denmark)

^c AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Aspirin; Atrial fibrillation; Clopidogrel; Edoxaban; Oral anti coagulation; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; EDOXABAN; PLACEBO; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRIDINE DERIVATIVE; THIAZOLE DERIVATIVE; TICLOPIDINE; VITAMIN K GROUP;

ACUTE HEART INFARCTION; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; DEATH; DRUG DOSE COMPARISON; EMBOLISM; HUMAN; META ANALYSIS; MORTALITY; NUMBERS NEEDED TO TREAT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BLOOD; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; COMPLICATION; DRUG POTENTIATION; OBSERVATIONAL STUDY; RISK; RISK ASSESSMENT; STROKE; THROMBOPHILIA;

ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; EMBOLISM; FACTOR XA INHIBITORS; HUMANS; MORTALITY; NUMBERS NEEDED TO TREAT; OBSERVATIONAL STUDIES AS TOPIC; PLATELET AGGREGATION INHIBITORS; PYRIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; RISK ASSESSMENT; STROKE; THIAZOLES; THROMBOPHILIA; TICLOPIDINE; VITAMIN K;

EID: 84940033920     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH15-05-0383     Document Type: Article

References (28)

1. Camm AJ, Lip GY, De Caterina R, et al.; ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Eur Heart J 2012; 33: 2719-2747.
2. Romero-Ortuno R, O'Shea D. Aspirin versus Warfarin in Atrial Fibrillation. Age Ageing 2012; 41: 250-254.
3. Boulanger L, Kim J, Friedman M, et al. Patterns of use of antithrombotic therapy and quality of anticoagulation among patients with non-valvular atrial fibrillation in clinical practice. Int J Clin Pract 2006; 60: 258-264.
4. Monte S, Macchia A, Pellegrini F, et al. Antithrombotic treatment is strongly underused despite reducing overall mortality among high-risk elderly patients hospitalized with atrial fibrillation. Eur Heart J 2006; 27: 2217-2223.
5. Sardar P, Chatterjee S, Wu WC, et al. New oral anticoagulants are not superior to warfarin in secondary prevention of stroke or transient ischaemic attacks, but lower the risk of intracranial bleeding: insights from a meta-analysis and indirect treatment comparisons. PLoS One 2013; 8: 77694.
6. Sardar P, Chatterjee S, Chaudhari S, et al. New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trials. J Am Geriatr Soc 2014; 62: 857-864.
7. Giugliano RP, Ruff CT, Braunwald E, et al. ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093-2104.
8. Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997; 50: 683-691.
9. Lumley T. Network meta-analysis for indirect treatment comparisons. Stat Med 2002; 21: 2313-2324.
10. Hoaglin DC, Hawkins N, Jansen JP, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Heal 2011; 14: 429-437.
11. Roskell NS, Lip GY, Noack H, et al. Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate. Thromb Haemost 2010; 104: 1106-1115.
12. Cameron C, Coyle D, Richter T, et al. Systematic review and network meta-analysis comparing antithrombotic agents for the prevention of stroke and major bleeding in patients with atrial fibrillation. Br Med J Open 2014; 4: 4301.
13. Rasmussen LH, Larsen TB, Graungaard T, et al. Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis. Br Med J 2012; 345: 7097.
14. Lip GY, Larsen TB, Skjoth F, et al. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. J Am Coll Cardiol 2012; 60: 738-746.
15. Skjoth F, Larsen TB, Rasmussen LH, et al. Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis. Thromb Haemost 2014; 111: 981-988.
16. Verdecchia P, Angeli F, Lip GY, et al. Edoxaban in the evolving scenario of nonvitamin K antagonist oral anticoagulants imputed placebo analysis and multiple treatment comparisons. PLoS One 2014; 9: 100478.
17. Dogliotti A, Paolasso E, Giugliano RP. Current and new oral antithrombotics in non-valvular atrial fibrillation: a network meta-analysis of 79,808 patients. Heart 2014; 100: 396-405.
18. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
19. Franchini AJ, Dias S, Ades AE, et al. Accounting for correlation in network meta-analysis with multi-arm trials. Res Synth Methods 2012; 3: 142-160.
20. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoid­ance of continuity corrections in meta-analysis of sparse data. Stat Med 2004; 23: 1351-1375.
21. Singer DE, Chang Y, Fang MC, et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 2009; 151: 297-305.
22. Banerjee A, Lane DA, Torp-Pedersen C, et al. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost 2012; 107: 584-589.
23. Olesen JB, Lip GYH, Lindhardsen J, et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a "real world" nationwide cohort study. Thromb Haemost 2011; 106: 739-749.
24. Connolly SJ, Eikelboom J, Joyner C, et al.; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806-817.
25. National Institute of Health and Care Excellence (NICE). Clinical guideline 180: The management of atrial fibrillation. www.nice.org.uk.
26. Royal College of Physicians. Sentinel Stroke National Audit Programme (SSNAP). Clinical audit first pilot public report; August 2013. Available at: https://www.rcplondon.ac.uk/projects/sentinel-stroke-national-audit-programme.
27. Lip GYH, Laroche C, Dan GA, et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace 2014; 16: 308-319.
28. NICE Implementation collaboration. Consensus: Supporting local implementation of NICE guidance on use of the novel (non-Vitamin K antagonist) oral anticoagulants in non-valvular AF. www.nice.org.uk.